Business
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026 Strong financial position with $147.1 million in cash and cash equivalents expected to support operations into the third quarter of 2027 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Neumora Therap
About this update from Neumora Therapeutics, Inc.
[{"type":"image","alt":"Neumora Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Neumora Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/35035d45290d68b78910fa3d659951f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4hTwC25zVvE7RhuPVFeG.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTc5/https://media.zenfs.com/en/globenewswire.com/35035d45290d68b78910fa3d659951f0","width":183,"height":40},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/4hTwC25zVvE7RhuPVFeG.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTc5/https://media.zenfs.com/en/globenewswire.com/35035d45290d68b78910fa3d659951f0","width":183,"height":40}},"lazy":false},{"type":"text","content":"KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026","length":141,"tagName":"p"},{"type":"text","content":"Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026 ","length":155,"tagName":"p"},{"type":"text","content":"Strong financial position with $147.1 million in cash and cash equivalents expected to support operations into the third quarter of 2027","length":136,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.","length":391,"tagName":"p"},{"type":"text","content":"“We focused on steady execution during the first quarter, highlighted by the full enrollment of the navacaprant KOASTAL‑2 and ‑3 studies with more than 400 patients per study. We look forward to the topline readout of these studies this quarter,” said Paul L. Berns, chairman and chief executive officer, Neumora. “Additionally, we reported the Phase 1b study with NMRA-511 demonstrating an unsurpassed clinical effect in Alzheimer’s disease agitation and we remain on track to report data from the MAD expansion cohort in the second half of 2026, with a Phase 2 study ant...